Report by Rakshit Josain
New Delhi: In a significant development for India’s public healthcare system, QDENGA has become the country’s first approved dengue vaccine, marking a major milestone in the fight against one of the nation’s most prevalent mosquito-borne diseases. The vaccine is expected to strengthen dengue prevention efforts, particularly in states that witness recurring outbreaks during the monsoon season.
Developed by Japanese pharmaceutical company Takeda, QDENGA is a live-attenuated tetravalent dengue vaccine designed to protect against all four dengue virus serotypes—DENV-1, DENV-2, DENV-3 and DENV-4. Protection against all four strains is important because infection with one serotype does not provide long-term immunity against the others, and subsequent infections may increase the risk of severe dengue.
According to clinical studies conducted in multiple countries, the vaccine has demonstrated effectiveness in reducing symptomatic dengue infections and lowering the risk of hospitalization due to severe disease. QDENGA is administered in a two-dose schedule, with the second dose given three months after the first.
Dengue remains a major public health concern in India, with thousands of cases reported annually. The disease, transmitted by the Aedes aegypti mosquito, causes high fever, severe headache, muscle and joint pain, skin rashes, and, in severe cases, bleeding complications and organ failure.
Health experts have welcomed the approval, saying vaccination could significantly reduce the disease burden when combined with robust mosquito-control measures. However, they stress that vaccination is not a substitute for preventive practices. Eliminating stagnant water, using mosquito repellents, wearing full-sleeved clothing, and maintaining clean surroundings will continue to play a critical role in preventing dengue transmission.
The vaccine’s rollout strategy, pricing, eligibility criteria, and inclusion in government immunization programmes are expected to be announced separately by the relevant health authorities. Public health specialists believe that wider access to the vaccine could help reduce hospitalizations, ease pressure on healthcare facilities during peak dengue season, and save lives.
With the approval of QDENGA, India has added a powerful new tool to its dengue prevention strategy, offering fresh hope in the battle against a disease that continues to challenge public health every year.
